Research programme: tyrosine kinase inhibitors - Concentra Biosciences
Latest Information Update: 28 May 2025
At a glance
- Originator Theseus Pharmaceuticals
- Developer Concentra Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastrointestinal cancer
Most Recent Events
- 28 May 2025 No recent reports of development identified for research development in Gastrointestinal-cancer in USA
- 13 Jul 2023 Theseus Pharmaceuticals expects to nominate lead candidate from the programme in the first half of 2024
- 04 Apr 2022 Vipergen establishes DNA Encoded Library (DEL)- based drug discovery partnership with Theseus Pharmaceuticals to develop small-molecule compounds for Cancer